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Nebulized ivermectin for COVID‑19 
and other respiratory diseases, 
a proof of concept, dose‑ranging 
study in rats
Carlos Chaccour1,2,3*, Gloria Abizanda4,5, Ángel Irigoyen‑Barrio6,7, Aina Casellas1,8, 
Azucena Aldaz5,6, Fernando Martínez‑Galán6, Felix Hammann9 & Ana Gloria Gil6,7
Ivermectin is a widely used antiparasitic drug with known efficacy against several single‑strain RNA 
viruses. Recent data shows significant reduction of SARS‑CoV‑2 replication in vitro by ivermectin 
concentrations not achievable with safe doses orally. Inhaled therapy has been used with success for 
other antiparasitics. An ethanol‑based ivermectin formulation was administered once to 14 rats using 
a nebulizer capable of delivering particles with alveolar deposition. Rats were randomly assigned into 
three target dosing groups, lower dose (80–90 mg/kg), higher dose (110–140 mg/kg) or ethanol vehicle 
only. A toxicology profile including behavioral and weight monitoring, full blood count, biochemistry, 
necropsy and histological examination of the lungs was conducted. The pharmacokinetic profile 
of ivermectin in plasma and lungs was determined in all animals. There were no relevant changes 
in behavior or body weight. There was a delayed elevation in muscle enzymes compatible with 
rhabdomyolysis, that was also seen in the control group and has been attributed to the ethanol dose 
which was up to 11 g/kg in some animals. There were no histological anomalies in the lungs of any 
rat. Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher 
plasma concentrations than females in the same dosing group (mean  Cmax 86.2 ng/ml vs. 26.2 ng/
ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group). All subjects had 
detectable ivermectin concentrations in the lungs at seven days post intervention, up to 524.3 ng/g for 
high‑dose male and 27.3 ng/g for low‑dose females. nebulized ivermectin can reach pharmacodynamic 
concentrations in the lung tissue of rats, additional experiments are required to assess the safety of 
this formulation in larger animals.
As of August 19, 2020, there have been more than 22 million COVID-19 cases causing over 785,000 deaths 
worldwide. In the absence of a vaccine, numerous efforts are ongoing to develop drug-based strategies to prevent, 
treat or reduce the transmission of the virus. Data on several drug regimens suggest lack of efficacy for lopinavir-
ritonavir1, hydroxychloroquine as  prophylaxis2 or even harmfulness such as high-dose hydroxychloroquine for 
 prophylaxis3 while  remdesivir4 and  dexamethasone5 seem to improve patients’ outcome.
Ivermectin is a widely used antiparasitic drug with known efficacy against several single-strain RNA viruses 
including  Dengue6,  Zika7 and other  viruses8. The effect on flaviviruses could be explained by a reduction of the 
viral penetration into the nucleus via an effect on the host´s importin alpha/beta19, inhibition of the viral  helicase8 
or yet to be described mechanisms.
Caly et al. showed a significant reduction of SARS-CoV-2 replication after incubating Vero cells, a cell line 
derived from African Green Monkey kidney epithelial cells, for 48 h with ivermectin concentrations not read-
ily attainable in vivo10. Yet, these findings stirred widespread interest and together with a preprint report of 
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potential benefit of a single dose of ivermectin 150 ug/kg on in-hospital mortality has resulted in extensive use 
of ivermectin for the treatment or prevention of COVID-19, particularly in Latin-America. There are currently 
27 clinical trials registered in clinicaltrials.gov testing ivermectin alone or in combination against COVID-19.
Despite of the mismatch between ivermectin´s pharmacokinetics and the  IC50 reported by Caly et al., the 
drug may still prove useful for COVID-19 patients given marginal in vivo effects against dengue in spite of even 
higher estimated in vitro  IC50 values (> 10 μM) in Vero  cells6,11, known anti-inflammatory  effects12,13 and potential 
additional immunomodulation through an interaction with nicotinic  receptors14. Another proposed mechanism 
is the increase of the airway epithelial cell expression of the angiotensin-converting enzyme II (ACE-2) viral entry 
receptor mediated by activation of nicotinic acetylcholine receptors (nAChR)15, primarily the α7 subtype. This 
would help explain the additional susceptibility of smokers to Covid-19. Inhibition of α7-nAChR may suppress 
this process, thereby reducing within-host infectivity and transmission. Krause et al. found a comparatively low 
α7-nAChR  IC50 for ivermectin of 0.156 μM, a concentration realistically attainable even on oral drug  dosing16.
Inhaled therapy could be used to instantaneously reach and maintain effective concentrations in lung tissue. 
Other authors have previously described successful delivery of antiparasitic drugs using nebulizers that create 
a particle size capable of reaching alveoli in hospital and community  settings17,18. We are only aware of a single 
previous study using nebulized ivermectin, Ji et al.19 exposed Sprague–Dawley rats to a known concentration 
of ivermectin in chamber air and determined the inhaled  LD50 at 4 h to be 3690 (2710–5010) mg/m3 and the 
no adverse events were seen in rats exposed to a concentration of 380 mg/m3 for 21 consecutive days. The study 
design of Ji et al., however seems intended as an environmental toxicity study, not to guide a therapeutic use of 
the drug.
Here we report of a pilot rat-model evaluating the feasibility of therapeutic delivery of nebulized ivermectin. 
The main objectives were to assess the ivermectin pharmacokinetics in plasma and lung tissue as well as safety 
of this formulation through a comprehensive toxicology profile.
Methods
Formulation. We unsuccessfully attempted to produce a water soluble-solution by combining surfactants 
such as polysorbate or co-solvents such as propylene glycol or glycerin. Given solubility issues and that ethanol 
does not interfere with ivermectin  pharmacokinetics20, ivermectin powder API was diluted in pure ethanol to 
reach three different concentrations, 7 mg/ml, 10 mg/ml and 14 mg/ml and kept in opaque flasks at 5 °C. Stabil-
ity tests using HPLC conducted one week after dilution showed no changes in the original concentrations. All 
solutions were used within one week of preparation.
Rats. We used adult, 12-weeks old, Sprague–Dawley rats that were kept in groups of 2–3 subjects of the same 
sex per cage at the animal research facilities of the University of Navarra. Light, temperature, humidity and feed-
ing conditions followed the local standard operating procedures. Rats in the intervention groups were identified 
as TM/TF (males/females) plus a correlative number 1–6. Rats in the control group were identified as VCM or 
VCF for male and female respectively. Cages were identified with the study name and each rat was marked with 
its individual code in the base of the tail using a non-toxic permanent marker.
Procedures. For the nebulization, we used a Micro Cirrus device (Intersurgical, Berkshire, UK) with a driv-
ing oxygen flow of 8 L/min which can deliver aerosol particles of 0.5–2 μm in diameter resulting in alveolar 
deposition. A volume of 3 ml of the solutions was used. A 22-mm elbow piece that covered the rats’ nose and 
mouth was used to deliver the cloud (Fig. 1). The oxygen flow was kept until the reservoir was empty at visual 
inspection for an average nebulizing time of 9 min. The reservoirs were weighed before and after the nebuliza-
tion to confirm the final weight was the same as the empty one, before the procedure.
The oral lethal concentration 50%  (LC50) for rats has been estimated by Merck in 42.8–52.8 mg/kg for males 
and 44.3–52.8 mg/kg for  females21. The rats for this study were randomly assigned into three groups: (a) lower 
dose, aiming at twice the lower boundary of the  LC50 for their sex; (b) higher dose, aiming at twice the upper 
boundary of the  LC50 for their sex and (c) controls receiving only the ethanol vehicle. The sample was chosen 
according to usual practice in dose-range finding pilots. Treatment groups included three males and three females 
each, rats from each sex were housed in separate cages. The first three males received the lower dose, the first 
three females received the lower dose, the remaining three in each cage were assigned to the missing dosing 
group and the last rat in each cage remained untreated.
The intervention was administered in dose-groups under anesthesia with ketamine and diazepam 75/5 mg/
kg, intraperitoneal, single dose. Post-administration, the rats were monitored until recovery for 60–90 min on 
a thermic blanket and then monitored daily using a modified Irwin  test22 until euthanasia. The weight of all 
subjects was recorded at baseline, day 3 and at the day of euthanasia. Additionally, a full blood count and a bio-
chemistry toxicology panel including total serum proteins, albumin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin, total cholesterol, glucose, creatinine, urea, creatine phosphokinase (CPK)and 
lactate dehydrogenase (LDH) was performed in one subject per sex/group at euthanasia.
Plasma samples for determination of ivermectin levels were obtained at 1, 4 and 24 h after administration 
and at the time of euthanasia (days 3, 5 or 7). Blood samples of 0.5 ml were obtained under brief induction 
anesthesia with inhaled isoflurane 1.5–2% from the retro orbital plexus, centrifuged and the plasma frozen at 
− 80 °C until processing.
A t the end of their corresponding study period (Fig. 2), subjects were euthanized using a  CO2 chamber. A 
macroscopic necropsy was performed in all subjects including external and in situ examination of all organs. 
The lungs and livers were extracted, measured and weighted separately. One lung and one liver sample from 
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every subject was preserved in formaldehyde and sent to Patconsult LAB (Barcelona, Spain) for histopathologi-
cal examination.
Ivermectin levels. Ivermectin plasma levels were determined using a variation of a previously described 
HPLC-FLD23 with a detection limit of 0.1 ng/ml.
Lung tissue (0.5 mg) was homogenized in 1 ml of acetonitrile using an Ultra-turrax homogenizer and the 
sonicated for 15 min, 100 mcl of the homogenized lung were processed in the HPLC-FLD using the plasma 
 methods24.
Calculations, data analysis and software. Given that ivermectin deposits in adipose  tissue25 and that 
differences in ivermectin’s PK based on body composition have been previously  described26, the dose per gram 
of body fat was calculated in all rats. The adipose weight of the rats according to sex was estimated using the 
formula described by Ferrel and  Koong27. Comparison of baseline characteristics was done using the Wilcoxon 
Rank Sum test in Stata 16 Software (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: 
StataCorp LLC). Body weigh-PK by sex graphs were done in Microsoft Excel (Microsoft corporation, 2018).
Data set checkout and visualizations of pharmacokinetic data were performed in GNU R (R Core Team 
[2020] R: A language and environment for statistical computing, version 3.6.3, R Foundation for Statistical 
Figure 1.  Nebulization procedure.
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Computing, Vienna, Austria, https ://www.R-proje ct.org/). Non-compartmental analysis (NCA) was performed 
using Pkanalix (Monolix version 2019R2. Antony, France: Lixoft SAS, 2019. https ://lixoft .com/produ cts/monol 
ix/). Peak plasma concentration ( Cmax ), and time to peak plasma concentration ( Tmax ) were read directly from 
the profiles. Terminal elimination half-life ( t1/2 ) was calculated as t1/2 = ln(2)/z after estimating z from the 
final two measurements of each profile. The area under the plasma concentration–time curve (AUC) from 0 to 
168 h post-dose ( AUC0−168h ) was calculated using the linear up/log down method. Mean plasma concentrations 
from 0 to 168 h post-dose are given as Cavg .,0−168h . Lung tissue concentrations were back-calculated from lung 
densities reported by El-Khatib et al. in Sprague–Dawley female rats aged 15–90 weeks28. At 15 weeks of age, the 
average lung density was about 0.4 g/cm3, and we therefore converted 1 g of lung tissue to a volume of 2.2 ml.
Ethics. All procedures were reviewed and approved by the Animal research ethics committee of the Univer-
sity of Navarra (Approval Number E11/20 from CEEA 002/20).
Regulatory compliance. All methods were carried out in accordance with relevant guidelines and regula-
tions.
Results
Baseline characteristics. The baseline characteristics of the rats in by sex is presented in Table 1. Male 
rats had an approximate median weight 100 g (50%) higher than females (p-value = 0.002) and different body 
composition resulted in females having three times the estimated adipose weight (median 92.9 vs. 29.1  g, 
p-value = 0.002).
Intervention and immediate recovery. The recommended minimal volume to generate nebula with the 
device used is of three ml, given that our formulation is ethanol/based, this volume set the minimal ethanol dose 
given with the intervention in 2.3 g (equivalent to 3 ml). All animals received the intervention uneventfully and 
recovered from anesthesia within 90 min. At the time of the first blood sample (1 h after the intervention), they 
showed slight instability and lethargy which was attributed to the alcohol dose and had recovered fully by the 
time of the second blood sample, 4 h after the intervention.
Ivermectin dose. The animals in the lower dose group received a median dose of 89 mg/kg of ivermectin, 
ranging 86–98 mg/kg for males and 88–95 mg/kg for females which correlates well with the target of twice the 
lower boundary of the oral  LD50. The animals in the higher dose group received a median dose of 121 mg/kg of 
ivermectin, ranging 108–116 mg/kg for males and 126–141 mg/kg for females which represents 2.0 to 2.2-fold 
the upper boundary of the oral  LD50 for males and 2.3 to 2.6-fold the upper boundary of the  LD50 for females. 
However, the significantly different adipose weight resulted in male rats receiving much higher doses of ivermec-
tin per gram of fat than females (3.2 to fourfold in the higher dose group, and 3.9 to 5.7-fold in the lower dose 
group), weights and doses of all animals are presented in Table 2.
All rats received 3 ml (2.3 g) of inhaled ethanol, which resulted in weight-adjusted ethanol doses of 6.1–7.7 g/
kg for males (Table S18) and 9.4–11.1 g/kg for females (Table S19) which is lower than or overlapping with the 
oral ethanol  LD50 described for rats of a similar age (10.0–11.2 g/kg)29.
Figure 2.  Summary and timeline of study procedures. TM#/TF#, CVM and CVF. 1One animal per sex and 
treatment group.
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Behavior, symptoms and weight. All animals had a normal behavior and central nervous system assess-
ment throughout the study according to the modified Irwin procedure (Tables S3-S17).
All animals had a normal weight for their age at baseline, except for one male (TM1) who was 17 g (5%) below 
the lower limit of the normality for 12 weeks (321 g).
All males except one in the lower dose group had lost weight at day three post intervention, ranging from 2 
to 4.2% of their baseline weight. The control male, nebulized with ethanol vehicle only, lost 3.5% of its baseline 
weight by day three. All males except one in the higher dose group that lost further 0.6%, had started to gain 
weight or recovered their baseline value at the time of euthanasia (Table S18). All females except two (one in the 
lower dose group and one in the higher dose group) had lost weight at day three post intervention, ranging from 
0.4 to 3.4% of their baseline weight. The control female lost 0.4% of its baseline weight by day three. All females 
had started to gain weight or recovered their baseline value at the time of euthanasia (Table S19).
Toxicology labs. Male rats had no significant hematological changes regardless of ivermectin dose group 
or ethanol dose adjusted by weight (Table S20). All but two female rats had a slight anemia with hemoglobin 
Table 1.  Baseline characteristics of the rats in each group. a Median (IQR) [n]. b n (Column percentage).
Variable
Sex
TotalMale Female
Baseline weight (g)a 346.9 (331.5–372.5) [7] 237 (218.8–249.5) [7] 277.55 (237–346.9) [14]
Fat weight (g)a 29.1 (27.5–31.8) [7] 92.9 (81.6–101.1) [7] 55.3 (29.1–92.9) [14]
Dosage
Dose (mg)b
 None 1 (14%) 1 (14%) 2 (14%)
 Lower dose 3 (43%) 3 (43%) 6 (43%)
 Higher dose 3 (43%) 3 (43%) 6 (43%)
Dose (mg/Kg)a 98.7 (86.5–112.8) [7] 96.0 (83.6–132.5) [7] 97.3 (86.5–116.5) [14]
Dose per gram of  fata 1.2 (1.0–1.3) [7] 0.3 (0.2–0.3) [7] 0.4 (0.2–1.2) [14]
Table 2.  Weight, body composition, doses, plasma and lung levels of all rats. **Below quantification limit. 
a Ferrel and Koong method.
Group Subject
Baseline 
weight (g)
Fat 
weight 
(g)a
Body fat 
(%)
Total 
dose 
(mg)
Dose 
(mg/kg)
Dose per 
gram of 
fat (mg/g)
Plasma 
levels 1 h 
(ng/ml)
Plasma 
levels 4 h 
(ng/ml)
Plasma 
levels 
24 h (ng/
ml)
Plasma 
levels 
72 h (ng/
ml)
Plasma 
levels 
140 h (ng/
ml)
Plasma 
levels 
168 h (ng/
ml)
Lung 
levels 
(ng/g) 
(time)
Lower 
dose 
males
TM1 303.9 24.69 8 30 98.7 1.2 55.0 29.1 81.8 74.6 – – 75.6  [72 h]
TM2 333.2 27.71 8 30 90.0 1.1 26.1 29.8 96.7 – – 25.9 110.6 [168 h]
TM3 346.9 29.12 8 30 86.5 1.0 36.4 48.3 80.0 – 38.2 – 141.2 [140 h]
Higher 
dose 
males
TM4 386.9 33.24 9 42 108.6 1.3 35.9 44.2 142.9 63.4 – – 592.9 [72 h]
TM5 360.6 30.53 8 42 116.5 1.4 52.5 39.6 186.7 – – 56.0 524.3 [168 h]
TM6 372.5 31.76 9 42 112.8 1.3 52.4 39.9 126.4 – 58.5 – 446.8 [140 h]
Higher 
dose 
females
TF1 211.6 77.35 37 30 141.8 0.4 9.8 9.9 33.6 15.0 – – 339.2 [72 h]
TF2 226.4 86.24 38 30 132.5 0.3 63.4 10.9 22.8 – – 13.2 94.7 [168 h]
TF3 237 92.91 39 30 126.6 0.3 11.2 8.4 58.6 – 13.4 – 170.6 [140 h]
Lower 
dose 
females
TF4 218.8 81.61 37 21 96.0 0.3 11.4 10.5 27.4 6.6 – – 250 [72 h]
TF5 251.2 102.23 41 21 83.6 0.2 40.9 8.1 20.7 – – 6.7 27.3 [168 h]
TF6 238.4 93.81 39 21 88.1 0.2 9.8 9.5 10.3 – 6.9 – 13.8 [140 h]
Control 
(m) CVM1 331.5 27.54 8 0 ** ** ** ** ** ** ** ** ** [168 h]
Control 
(f) CVF1 249.5 101.09 41 0 ** ** ** ** ** ** ** ** ** [168 h]
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levels 0.1 to 1.7 g/dL below the minimum normal value. Additionally, all females had total red blood cells below 
the normal limit (median 0.8 × 106/ul) and slightly increased mean corpuscular values (median 3.5 fl above the 
upper normal limit) (Table S21).
Animals in both groups presented a delayed increase (two to threefold the upper level of normality) in cre-
atine kinase (CPK) and lactate dehydrogenase (LDH), this effect was seen earlier in females (all euthanized after 
140 h post administration) than in males (only those euthanized at 168 h). Except for one female in the higher 
ivermectin dose which had AST/ALT values 1.5-fold the upper limit, liver enzymes and bilirubin were normal 
or below the lower limit in all rats. Two males and all but one female had slightly increased creatinine values. All 
blood biochemistry results are presented in Supplementary Tables S1 and S2 for males and females respectively.
Necropsy. One male in the higher dose group (TM6) had a patchy pattern in both lungs (Figure S1). There 
were no macroscopic findings in the thoracic or abdominal organs of any other subject. The absolute and rel-
ative-to-body weights of lungs and livers from all subjects where within normal values (Tables S22 and S23). 
There were no pathologic changes in the histology of liver and lungs samples examined, including the lung 
sample from the male rat with a macroscopic patchy pattern (Figure S2).
Pharmacokinetics. Individual plasma profiles by dose group and sex are shown in Fig. 3. Secondary phar-
macokinetic parameters in plasma are given in Table 3. Concentrations in lung tissue remained detectable in all 
animals at time of necropsy (72–168 h, Table 2, Fig. 4).
The relationship between the ivermectin dose per gram of fat and the plasma concentrations at 1, 4 and 24 h 
is shown in Fig. 5.
Discussion
Dose and body composition. Although the total and weight-adjusted ivermectin doses were comparable 
between males and females in both dose groups, the higher estimated adipose weight of female rats resulted in 
a 3 to fourfold dose of ivermectin per gram of fat. Ivermectin accumulates in adipose  tissue25, this deep com-
partment affects systemic concentrations of the drug in subjects with different body composition and sex-based 
differences have been well described  before26,30. In this experiment there was a direct relationship between the 
dose per gram of fat and the plasma levels reached at 1, 4 and 24 h. Nebulized ivermectin reached a  Cmax twice as 
high and had an AUC 4 to sixfold higher in male rats regardless of the dosing group. There was also a tendency 
for lung levels of male rats to be higher regardless of the dosing group.
Toxicology. The hematological changes observed in most female rats, regardless of dosing group, (mild 
macrocytic anemia and reduced total RBC) are already present in animals euthanized 72 h after the interven-
tion and could either precede the intervention or be the consequence of the proportionally larger blood loss due 
sampling in this group. The elevated CPK and LDH observed 5–7 days after the intervention seem to be of mus-
cular origin given normal values of bilirubin and liver enzymes in all rats; we hypothesize these changes are in 
relationship with the high ethanol dose received (up to 11 g/kg of ethanol which is the equivalent of one standard 
alcohol unit per kg or weight) since they are also present in the control animals that did not receive any ivermec-
tin. Non-traumatic rhabdomyolysis has been reported before in relationship with acute alcohol  intoxication31 
and this is compatible with the slight increase in creatinine values seen in most animals. Alcohol intoxication 
Figure 3.  Individual plasma concentration–time curves stratified by sex and dose administered (lower 
dose = 84–98 mg/kg, higher dose 106–140 mg/kg).
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is also compatible with the described initial weight loss and posterior recovery. The anesthesia used during the 
intervention and for the PK sampling could have played a role in the CPK/LDH elevation but isoflurane is not 
known to increase  LDH32 and ketamine-induced elevations are generally of smaller  magnitude33. The ethanol 
dose that a 70-kg human adult would receive with a nebulized 3 ml solution would be 2.36 g (the equivalent of 
1/5 of one standard alcohol unit) or 300-fold less than the dose received by the rats in this study. In any case, care 
must be taken as recreational use of inhaled ethanol can be used in binge-like patterns, even if immediate safety 
concerns are relatively  minor34.
Pharmacokinetics. Upon visual inspection most concentration–time curves show a biphasic profile. We 
attribute this to double absorption first through inhalation (fast uptake) and then oral absorption (slower uptake) 
of swallowed drug. It is notable that the second peak is higher than the first, indicating that the majority of drug 
was swallowed. This is a common phenomenon in nebulized vehicles where subjects are not skilled at inhalation 
or unable to comply with instructions. We therefore assume that considerably higher lung exposure could be 
achieved in intubated animals. Nebulized administration of ivermectin to human volunteers would presumable 
also allow for better deposition of the drug in the respiratory tract and lower circulating levels.
We attempted to characterize the pharmacokinetic behavior and fractions absorbed via both ways using a 
population-based approach. As the initial uptake in the lungs occurs very early in the profiles where sampling was 
Table 3.  Secondary pharmacokinetic parameters derived from non-compartmental analysis of plasma 
concentration–time profiles. AUC 0–168 h, area under the plasma concentration–time curve from time zero 
to 168 h;  Cavg 0–168 h, mean plasma concentration from 0 to 168 h, Clast, last observed plasma concentration, 
 Cmax, maximum plasma concentration; t1/2, terminal plasma elimination half-life; SEM, standard error of the 
mean;  Tmax, time to reach  Cmax. (a) media.
Dose group Sex Units
Cmax Tmax (a) Clast Cavg 0–168 h t1/2 AUC 0–168 h
(ng/mL) (h) (ng/mL) (ng/mL) (h) (ng*h/mL)
Lower dose
Female (n = 3)
Mean (SEM) 26.2 (8.9) 24 6.7 (0.1) 4.7 (1) 127.5 (52.7) 1610.5 (275.1)
Range 10.3–40.9 1–24 6.6–6.9 3.0–6.4 23.4–193.7 1330.3–2160.7
Male (n = 3)
Mean (SEM) 86.2 (5.3) 24 46.2 (14.6) 17.3 (1.5) 175.7 (92.9) 9679.6 (958.9)
Range 80.0–96.7 24–24 25.9–74.6 14.9–20.0 75.8–361.3 8387.0–11,552.8
Higher dose
Female (n = 3)
Mean (SEM) 51.8 (9.2) 24 13.9 (0.6) 7.5 (1.0) 370.8 (327.6) 3128.2 (526.2)
Range 33.6–63.4 1–24 13.2–15.0 5.7–9.2 41.3–1026.0 2291.6–4099.3
Male (n = 3)
Mean (SEM) 152.0 (18.0) 24 59.3 (2.2) 25.0 (1.5) 70.1 (14.6) 13,461.7 (2447.9)
Range 126.4–186.7 24–24 56.0–63.4 23.1–27.9 40.9–86.4 9707.4–18,060.1
Figure 4.  Lung concentrations at necropsy for all animals stratified by dose administered and sex (lower 
dose = 84–98 mg/kg, higher dose 106–140 mg/kg).
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not frequent, we were unable to construct robust models. Future trials could overcome this by more intensively 
sampling subjects during the first hours post-dose.
Achieving pharmacodynamic targets. The highest observed plasma concentration was 186.7 ng/mL 
which corresponds to 0.21 μM/L and is clearly below the  IC50 ~ 2 μM reported by Caly et al.10. Previous experi-
ence in Dengue virus infection with the translation of in vitro results to effectivity in human subjects has shown 
that Vero cell results should be interpreted qualitatively, not quantitatively. The actual  IC50 in humans and even 
respiratory epithelial cells may be quite different.
Figure 5.  Relationship between dose per gram of fat and ivermectin plasma levels at 1, 4 and 24 h after 
nebulization in rats.
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Concentrations are, however, above the nicotinergic acetylcholine receptor (nAChR)  IC50 for ivermectin as 
estimated by Krause et al.16. Lung tissue concentrations in male rats in the high-dose arm were well above this 
concentration after 72–168 h (Figure S3). Without a more thorough understanding of the absorption process, it 
is difficult to extrapolate what concentrations could be achieved with proper inhalation technique. It is, however, 
safe to say that ivermectin lung delivery with nebulized formulations can maintain detectable concentrations 
for 7 days.
The delivery method investigated here is not directly translatable to human clinical trials. Safety has to be 
demonstrated not only for ivermectin but also the ethanol vehicle. Our experience in man with ivermectin is 
with oral formulations only (sporadic case reports of compassionate use of veterinary parenteral products not 
considered). Oral bioavailability is not known, and it is conceivable that absorption via lung tissue is more 
complete as there is no first-pass effect compared to oral administration. We may therefore see higher, possibly 
toxic, systemic exposure on inhalation. Preliminary safety and dose-finding studies should be conducted with a 
second arm with oral dosing of the same amounts to quantify relative bioavailability.
Ivermectin has shown in vitro and in vivo effects against other flaviviridae. How well the respective modes 
of action translate to SARS-CoV-2 is under investigation. Until we have more appropriate in vitro results for 
key steps such as viral entry via ACE2 receptors or nicotinic receptors, or viral replication, drug regimen design 
will be difficult.
Other potential disease targets. Ivermectin is efficacious against several helminths of human and 
veterinary importance that have a pulmonary phase during their  lifecycle35. There are raising concerns about 
emerging anti-helminthic resistance and its potential impact on human health and  livelihood36, targeting these 
parasites while they are in the lungs (some of them with extended lung residence periods) with much higher 
concentrations than usually available after oral administration provides a potential answer to these concerns.
In human medicine, this could impact individual care of patients with Soil transmitted helminths, includ-
ing those with disseminated  strongyloidiasis37 in whom oral administration of the ivermectin is not always 
 successful38,39.
Another potential application is on the treatment or prevention of helminths currently considered not sus-
ceptible to ivermectin like Schistosoma mansoni, which expresses a variant of ivermectin’s primary target, the 
glutamate-gated chloride channels, that is only susceptible to a concentration of 1 μM, which is not readily 
attainable with oral doses but can be reached in the lung with a nebulized formulation.
Additionally, ivermectin’s anti-inflammatory properties may serve as primary or adjuvant therapy for res-
piratory diseases with an inflammatory component caused by chemical agents or  pathogens35,40 as well as local 
and metastatic  cancer41.
Limitations of this study. This proof-of-concept study could be considered a pilot given the reduced 
number of animals used, other limitations include that a single measure from the lung concentration was taken 
at any given point which prevents the assessment of whether there is differential deposit within an individual 
lung or that there was no concurrent control for the toxicology of rats euthanized at 72 or 140 h. Additionally, 
the formulation was administered by nose and mouth exposure, hence, the lung levels achieved may not reflect 
those potentially achieved in a human with active inhalation.
We acknowledge that an ethanol-based formulation administered with a system that requires a high flow of 
oxygen was appropriate for proving the concept but not for scale up, further investment into formulation devel-
opment would be needed to pursue this route of administration for any potential indication.
Next steps. The finding that ivermectin concentrations with potential for pharmacodynamic effect were 
measured in the lungs seven days after inhaled therapy warrant additional research on the potential use of 
nebulized ivermectin for susceptible respiratory diseases including COVID-19. The immediate next step is the 
conduction of an extended animal model in rodent and non-rodent species to collect the additional safety data 
required for a first administration in humans and potentially, the use of animal models of infection to assess the 
efficacy of this therapy against relevant pathogens including SARS-CoV-2, helminths and possibly inflammatory 
as well as neoplastic diseases proper of the lung tissue.
Conclusion
This study provides evidence that ivermectin can be delivered in high concentrations to rat lungs by nebuliza-
tion, but this warrants additional research to determine safety and efficacy, not direct extrapolation to humans 
via compassionate use or accelerated approval.
Data availability
All study data is contained within this manuscript and the supplementary material.
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